United States Patent 9,150,552 (US9150552): Scope, Claim Construction Signals, and US Patent Estate for Cystic Fibrosis Form I Solid-State Polymorph Methods
US 9,150,552 is a US method-of-treatment patent that narrows not only to cystic fibrosis (CF) patients with a specific CFTR genotype (Phe508 deletion, “ΔPhe508” class), but also to an administration of a specific small-molecule API in a defined solid-state form (Form I) with X-ray powder diffraction (XRPD) peak windows and particle size distribution thresholds. The claims are drafted to create a technical barrier against generics attempting to launch by substituting other polymorphs/particle forms or by using a different solid form not matching the asserted XRPD pattern.
Executive snapshot
- Claim core: CF treatment by administering 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in Form I plus specified excipient/solid-state characteristics embedded through XRPD and particle size limitations.
- Genotype limitation: CF patients with a defective CFTR gene causing deletion of phenylalanine at position 508 (ΔPhe508 context), including dependent claims specifying two copies.
- Form I is the gatekeeper: claims 3–20 lock Form I by Cu Kα XRPD peak positions and “substantially similar” diffraction patterns to specific figures.
- Particle engineering barrier: claims 21–22 restrict D90 ≤ ~82 μm and D50 ≤ ~30 μm, tightening process and formulation freedom for challengers.
- Practical implication: A Paragraph IV or non-infringing design-around is unlikely to succeed without proving that the ANDA product does not meet the XRPD peak set and particle size criteria for Form I (or challenges validity such as lack of enablement, indefiniteness, or prior art).
What do the claims of US 9,150,552 protect: method-of-treatment, specific polymorph Form I, or both?
Answer: Both. US 9,150,552 protects a method of treating CF that is defined by (i) patient genotype, (ii) drug identity, and (iii) an administrable solid-state Form I proven by XRPD peak patterns (and in narrower dependents, particle size distribution).
Claim 1: the metes-and-bounds anchor
Independent claim 1 ties together four separate constraints:
- Disease and method: treating cystic fibrosis in a patient.
- Patient genotype: defective CFTR gene with deletion of phenylalanine at position 508 (ΔPhe508).
- Drug substance identity: a specific chemical entity (the benzoic-acid/pyridine-cyclopropylcarboxamide scaffold with difluorobenzo[d][1,3]dioxole substitution).
- Solid form limitation: the chemical is “characterized as Form I and [another chemical descriptor] N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide.”
Key scope signal: claim 1 does not merely mention Form I; it requires that the administered material is Form I, meaning an accused product must satisfy Form I identity as framed by the dependent XRPD claims.
Claim 2: zygosity limitation
Claim 2 further limits to patients with two copies of the defective allele (homozygous or equivalent “two copies” interpretation). This narrows medical applicability and can matter for infringement if the accused product’s labeling or intended patient population differs.
Claims 3–20: XRPD pattern windows and “substantially similar” figures
These dependents define Form I by peak position ranges under Cu Kα radiation:
- Examples of window-based constraints:
- 15.2–15.6°
- 16.1–16.5°
- 14.3–14.7°
- And more specific dependents pin individual peaks or narrower windows (e.g., 14.5, 14.8, 17.8, 16.6, 7.8, 26.0, 21.6, 23.3).
- Broader dependents add:
- claim 19: diffraction pattern substantially similar to FIG. 1
- claim 20: diffraction pattern substantially similar to FIG. 2
Key scope signal: the “substantially similar” wording increases enforcement leverage because it can be argued to cover small measurement variability, batch-to-batch differences, and instrument drift. For a generic, that also raises the litigation risk because they must establish non-substantial similarity, not just a slightly different peak set.
Claims 21–22: particle size distribution thresholds
- D90 about 82 μm or less (claim 21)
- D50 about 30 μm or less (claim 22)
Key scope signal: These clauses can be used to argue infringement even if XRPD peak positions are matched but the particle size distribution is outside the stated thresholds. It also supports a process-and-particle design around only if the accused product intentionally uses coarser particles (or different milling/grinding) that may affect dissolution and bioavailability.
How is “Form I” defined in US 9,150,552 and what XRPD peak evidence is needed for infringement?
Answer: Form I is defined by XRPD Cu Kα peak position windows and by dependents that specify narrow windows for individual peaks plus “substantially similar” diffraction patterns to specified figures. This is the primary evidentiary battleground.
Peak mapping from the asserted claim text
Form I is asserted through these dependent peak patterns (subset shown in the order you provided):
-
Broad peak windows (claim 3):
- 15.2–15.6°
- 16.1–16.5°
- 14.3–14.7°
-
Narrowed dependent peaks (claims 4–18):
- claim 4: 15.4°, 16.3°, 14.5°
- claim 5: + 14.6–15.0°
- claim 6: + 14.8°
- claim 7: + 17.6–18.0°
- claim 8: + 17.8°
- claim 9: + 16.4–16.8°
- claim 10: + 16.6°
- claim 11: + 7.6–8.0°
- claim 12: + 7.8°
- claim 13: + 25.8–26.2°
- claim 14: + 26.0°
- claim 15: + 21.4–21.8°
- claim 16: + 21.6°
- claim 17: + 23.1–23.5°
- claim 18: + 23.3°
-
Figure-based coverage (claims 19–20):
- substantially similar to FIG. 1
- substantially similar to FIG. 2
Litigation leverage created by the claim drafting
- Multiple independent peak windows: The claim doesn’t rely on one signature peak. It requires a consistent pattern across several angles.
- Hierarchical dependence: If an accused product satisfies the highest-dependent claim (e.g., includes every additional peak window), it necessarily satisfies the independent plus all intermediate dependents.
- “About” language via particle size: “about” is used for D90/D50, creating a range for expert testimony that favors the patentee if the measurement variability is argued as within ordinary tolerances.
What a generic would need to rebut (conceptual, not procedural)
To avoid infringement under these claim structures, the ANDA/505(b)(2) applicant typically must show one of:
- the formulation does not contain the claimed Form I (XRPD pattern differs materially), or
- it lacks the specific peak set within the listed windows under the asserted measurement conditions, or
- particle size distribution fails the D50/D90 thresholds where those narrower dependents are asserted.
Which molecules and what drug identity signals exist in the claim: what is the “API + Form I” combination?
Answer: The claims identify a specific small-molecule core and require its administration in a defined solid-state “Form I” form, as well as referencing another named moiety descriptor in the claim text. The method-of-treatment claim structure indicates the patentee is treating the solid-state form as a limiting feature on the administered drug.
Scope interpretation based on claim text
- The chemical identity is explicit enough that a chemical comparison expert can attempt to match or exclude structural variants.
- The solid form is not defined by process parameters; it is defined by measured XRPD and particle size distributions, which is more enforceable than process-only definitions.
Commercial implication
This drafting approach is aimed at creating differentiation even when the active ingredient is known or appears in earlier patents or literature, by anchoring infringement to a particular crystalline/solid state.
When does US 9,150,552 expire and how does it interact with regulatory exclusivities?
Answer: This analysis cannot be completed from the claim text alone. The expiration date depends on filing/priority dates, patent term adjustments, and continuation history. Regulatory exclusivity (e.g., pediatric exclusivity, orphan drug exclusivity, 5-year NCE exclusivity, 7-year orphan if applicable) depends on the underlying FDA approval record and Orange Book listing. Without those data, a complete and accurate exclusivity timeline cannot be produced.
What is the Orange Book status of US 9,150,552 for cystic fibrosis drugs with ΔF508 patients?
Answer: This analysis cannot be completed from the claim text alone. Orange Book status requires the specific NDA/ANDA listing and the listed patents with relevant expiration dates and exclusivity codes. A correct “Orange Book status” statement must map the patent to its FDA-listed reference product(s) and listed use codes.
How strong is the patent estate for Form I solid-state methods: what claim features increase or decrease enforceability?
Answer: Enforceability is bolstered by (i) multiple XRPD peak constraints across angles, (ii) additional narrow peak dependents, (iii) “substantially similar” figure language, and (iv) particle size distribution limitations. Potential vulnerabilities are not assessable from claim text alone, including whether XRPD peaks are sufficiently supported in the specification or whether earlier disclosures exist.
Strength factors in the provided claim set
- Technical specificity: XRPD peak position windows are narrow enough to be used as an infringement yardstick.
- Layered limitations: dependent claims allow partial satisfaction arguments and stratified infringement theories.
- Measurement-linked definitions: the claims tie the solid state to a standard analytical modality (Cu Kα XRPD).
- Form I as limiting administered entity: “administering … characterized as Form I” constrains the accused material, not only the patient selection.
Potential litigation fault lines created by these claim features
- Instrument/condition sensitivity: XRPD peak position can vary with instrument calibration, sample prep, and diffractometer geometry. The patent counters with narrow “about” and “substantially similar” wording, but litigation often turns on expert interpretation.
- “Substantially similar” ambiguity: courts may construe “substantially similar” through the intrinsic record. That can cut both ways depending on how crisp the specification’s reference figures are.
- Particle size distribution as a practical limit: particle size can be manipulated, but that manipulation can affect performance, potentially making the design-around commercially difficult.
What patent landscape issues matter most for a generic challenger: polymorph substitution and particle engineering
Answer: The highest-risk design-around is changing polymorph identity while retaining performance. The highest-risk litigation strategy for a generic is asserting that the active ingredient is the same while claiming the solid form differs without meeting the XRPD and particle criteria embedded in the dependents.
Generic entry risk created by the claim architecture
- Polymorph-only workaround may fail: If the alternative polymorph still shows “substantially similar” diffraction patterns to the cited figures, it may still land in the claim.
- Particle size workaround may fail: Even if XRPD is not matched, accused products could still be asserted under XRPD dependents if XRPD is close enough, or under particle size dependents if XRPD is matched.
- Lot-to-lot variability risk: Solid state form and PSD can vary with manufacturing conditions. That variability can create infringement exposure if any lot matches the claim-defined Form I profile.
What other US patents typically surround a Form I solid-state estate for CF ΔF508 therapies?
Answer: A full “other patents in the landscape” mapping requires patent numbers, assignees, and the family/prosecution history. That cannot be produced from the claim excerpt.
Key Takeaways
- US 9,150,552 is a solid-state-defined method-of-treatment patent that requires both ΔPhe508-class CFTR patient selection and administration of the claimed API in a specific XRPD-defined Form I, with additional narrow dependents on particle size (D90 and D50).
- The XRPD peak windows and figure-based “substantially similar” language create the central infringement test and the main non-infringing design-around pathway.
- Particle size distribution thresholds add a second technical constraint that can defeat design-arounds even when crystalline form is close.
- Expiration, Orange Book linkage, and the breadth of the surrounding patent estate cannot be determined from the claim text provided; those require linkage to the FDA listing and full bibliographic data.
FAQs
1. What do the dependent XRPD peak claims (3–18) require, in practical infringement terms?
They require that Form I material used for dosing produces XRPD peaks at specified angle ranges and single representative peaks (e.g., 14.5°, 15.4°, 16.3°, 17.8°, 21.6°, 23.3°, 26.0°, plus additional windows), under Cu Kα diffraction conditions.
2. How does “substantially similar to FIG. 1/FIG. 2” affect a generic’s design-around?
It can broaden coverage beyond exact peak window compliance, letting the patentee argue infringement when the overall diffraction pattern matches the cited figures within an expert-defined tolerance.
3. Are the method claims limited to homozygous ΔPhe508 patients?
Claim 2 specifically limits to patients with two copies of the defective gene, but claim 1 itself covers “a defective gene” with deletion at phenylalanine position 508 without the two-copy limitation.
4. What is the role of particle size distribution limits (D90/D50) in claim scope?
They impose additional constraints on the administered material’s PSD. If asserted, an accused product must be within the specified D90 and D50 “about” thresholds.
5. Can a generic avoid infringement by switching polymorphs while keeping the same API?
The claim is explicitly tied to “Form I” defined by XRPD peaks. A polymorph swap could avoid infringement only if the product does not satisfy the Form I XRPD signature as claimed, and (if asserted) also avoids the D50/D90 PSD thresholds.
References (APA)
- Provided claim text for U.S. Patent 9,150,552 (US9150552).
